What a 503B Outsourcing Facility Means for You
FDA-established designation raising the national standard for quality, safety, and consistency.
Large-Batch Office-Use Medications
New Era is advancing healthcare with the development of its new 503B FDA-registered Outsourcing Facility.
A 503B facility is authorized to compound large-batch, "office-use" medications for hospitals, clinics, and physician offices—without the need for a patient-specific prescription.
The FDA established this designation to raise the national standard for quality, safety, and consistency in compounded medications.
cGMP Standards
503B outsourcing facilities must follow the same Current Good Manufacturing Practices (cGMP) required of pharmaceutical manufacturers.
- Validated production systems & environmental controls
- Sterility assurance programs & quality documentation
- Independent third-party laboratory testing
- Comprehensive quality documentation
Understanding cGMP Compliance
Pharmaceutical quality impacts every patient, every day. The U.S. Food and Drug Administration (FDA) enforces strict standards to ensure that all medications meet the highest levels of safety, strength, and purity.
The foundation of these standards is the Current Good Manufacturing Practice (cGMP) regulation. cGMPs require pharmaceutical manufacturers to maintain systems that guarantee the proper design, control, and monitoring of facilities and processes throughout production.
Quality Management Systems
Establishing robust quality management systems that ensure consistency and prevent contamination or error in every batch.
Verified Raw Materials
Sourcing only verified raw materials from qualified suppliers with complete traceability documentation.
Validated Procedures
Following validated operating procedures and investigating and correcting any deviations immediately.
Continuous Improvement
The "C" in cGMP means manufacturers must continually adopt the latest technologies and practices.
Strict Sterile Conditions
At New Era, each formulation is produced under strict sterile conditions, monitored daily through environmental sampling and quality checks.
Every batch undergoes independent third-party laboratory testing for sterility, endotoxins, and potency before release—ensuring the highest standard of pharmaceutical integrity.
Because these FDA requirements are so demanding, only a limited number of compounders in the U.S. meet the 503B designation. New Era's new facility, built from the ground up for 503B compliance, represents a significant milestone for Puerto Rico's healthcare and pharmaceutical industry.
Learn More at FDA.gov
Experience the 503B Difference
Partner with a facility built from the ground up for FDA compliance and pharmaceutical excellence.
Become a Provider